Oxford BioDynamics (LON:OBD) Sets New 1-Year Low – Here’s What Happened

Oxford BioDynamics Plc (LON:OBD) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.08 and last traded at GBX 0.12, with a volume of 242467219 shares changing hands. The stock had previously closed at GBX 0.15.

Oxford BioDynamics Trading Down 20.0%

The company has a current ratio of 0.88, a quick ratio of 2.80 and a debt-to-equity ratio of 457.97. The firm has a market capitalization of £5.15 million, a P/E ratio of -0.15 and a beta of 0.42. The firm has a 50-day moving average of GBX 0.19 and a two-hundred day moving average of GBX 0.23.

Oxford BioDynamics (LON:OBD) last released its earnings results on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter. The business had revenue of GBX 69 million during the quarter. Oxford BioDynamics had a negative net margin of 1,018.54% and a negative return on equity of 316.67%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.